RELITECT has become the latest life sciences company to move into BioCity Scotland.

The move to the life sciences incubator comes shortly after the company received backing of £750,000 to build its internal research and development capability, and to manufacture and test prototype devices.

Relitect is developing an electronic device able to detect low levels of biomarkers, which has the potential to be used in clinical diagnostics and drug development.

The team based at BioCity Scotland will lead the research and development required to fully commercialise the technology.